RxDoctor Payments Data

Sharon Lee, MD

Family Medicine · Mission, KSNPI 1154439081

Payments from drug & device makers

$7,529in general payments, 2019–2025

Across 433 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$1K
  • Johnson & Johnson$756
  • Napo Pharmaceuticals Inc$689
  • Merck$486
  • Lilly USA, LLC$335
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$1272%
  • Food & beverage$7,20396%
  • Education$2003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,529 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$36,227
Medicare patients
35
Services billed
1,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala141$581,724
TriumeqAbacavir/Dolutegravir/Lamivudi79$296,109
CabenuvaCabotegravir/Rilpivirine43$205,241
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf39$199,453
JulucaDolutegravir/Rilpivirine32$129,230
RukobiaFostemsavir Tromethamine14$124,117
PrezcobixDarunavir/Cobicistat24$65,197
DovatoDolutegravir Sodium/Lamivudine15$51,808
CompleraEmtricita/Rilpivirine/Tenof Df13$47,941
TrulicityDulaglutide30$35,598
MounjaroTirzepatide32$34,664
TivicayDolutegravir Sodium13$33,436
DescovyEmtricitabine/Tenofov Alafenam12$29,823
MytesiCrofelemer11$27,953
OzempicSemaglutide25$23,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Cabenuva, Juluca, Rukobia, Dovato$2,877$839,941196 claims
GileadBiktarvy, Descovy$1,296$611,548153 claims
Janssen Products, LPSymtuza$200$199,45339 claims
Johnson & JohnsonPrezcobix, Complera$756$113,13837 claims
Lilly USA, LLCTrulicity, Mounjaro$335$70,26362 claims
Napo Pharmaceuticals IncMytesi$689$27,95311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Mission

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →